Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07259955
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
PF-07259955 is an experimental small molecule drug developed by Pfizer as a topical "soft" Janus kinase (JAK) inhibitor. It was designed for the treatment of atopic dermatitis, with the intent to minimize systemic exposure and associated side effects. The drug acts by inhibiting JAK enzymes, which are involved in cytokine signaling pathways that contribute to inflammation in conditions like atopic dermatitis. PF-07259955 was formulated as a cream and evaluated in a Phase 1 clinical trial for safety and tolerability when applied to the skin of healthy adults. Following completion of this early-phase study, development of PF-07259955 was discontinued[1][2][4][8].
02
Targets
Beyond the preview
Go deeper on PF-07259955.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07259955.